Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $8.81 EPS

Key Points

• Rallybio reported quarterly EPS of $7.53, surpassing analysts’ expected loss of $1.28 by $8.81. Despite the beat, the company posted a negative 55.79% return on equity and a negative 911.07% net margin.
• Shares traded around $16.19, near the company’s 12-month high of $17.57, while the stock’s consensus analyst rating remained “Sell.”
• Insiders purchased 146,568 shares worth roughly $2.05 million over the past 90 days, and institutional investors own 90.34% of the company. Rallybio is developing therapies for rare genetic diseases, including its lead program for congenital athymia.

Rallybio (NASDAQ:RLYB - Get Free Report) posted its earnings results on Thursday. The company reported $7.53 earnings per share for the quarter, beating analysts' consensus estimates of ($1.28) by $8.81, FiscalAI reports. Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.

Rallybio Price Performance

Rallybio stock traded up $0.05 during mid-day trading on Thursday, hitting $16.19. The company's stock had a trading volume of 27,117 shares, compared to its average volume of 165,800. Rallybio has a 12 month low of $3.20 and a 12 month high of $17.57. The business has a 50 day moving average price of $15.98 and a 200-day moving average price of $11.29. The stock has a market cap of $85.77 million, a price-to-earnings ratio of -3.73 and a beta of -0.90.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Rallybio in a report on Friday, May 8th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company has a consensus rating of "Sell".

Insiders Place Their Bets

In other news, major shareholder Adar1 Capital Management, Llc acquired 10,200 shares of the firm's stock in a transaction on Tuesday, May 19th. The stock was acquired at an average price of $13.98 per share, for a total transaction of $142,596.00. Following the completion of the acquisition, the insider owned 926,352 shares in the company, valued at $12,950,400.96. This trade represents a 1.11% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders acquired 146,568 shares of company stock valued at $2,050,669 over the last 90 days. 10.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC lifted its stake in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock valued at $219,000 after buying an additional 373,821 shares in the last quarter. Renaissance Technologies LLC lifted its position in shares of Rallybio by 16.9% in the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock valued at $573,000 after acquiring an additional 120,892 shares in the last quarter. Susquehanna International Group LLP boosted its stake in shares of Rallybio by 485.9% in the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock worth $68,000 after acquiring an additional 113,031 shares during the period. XTX Topco Ltd grew its position in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock worth $67,000 after purchasing an additional 38,205 shares in the last quarter. Finally, Geode Capital Management LLC raised its stake in Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock valued at $170,000 after purchasing an additional 2,996 shares during the period. 90.34% of the stock is owned by hedge funds and other institutional investors.

Rallybio Company Profile

Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source